Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments

Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments

ObjectiveThe surgical treatment of the primary site has been a subject of controversy in patients with de novo metastatic breast cancer. In recent years, studies using large databases and retrospective analyses have provided evidence of the survival benefits of localized surgery for these patients....

Full description

Bibliographic Details
Main Authors: Guanyu Lu, Lin Jia, Ruohan Yang, Yutong Liu, Zheng Lv, Jiuwei Cui
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
stage IV
breast cancer
HER2-positive
surgery
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1308854/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1308854/full

Similar Items